receptors. 2 Although numerous receptors are involved, they share common downstream signaling pathways, providing suitable molecular targets for pharmacological interventions. One of the major pathways leading to cellular proliferation, migration, and survival is relayed by phosphatidylinositol 3′-kinase (PI3K). [6] [7] [8] Previously, we were able to demonstrate that platelet-derived growth factor β receptor (βPDGFR)dependent activation of PI3K in SMCs promotes cell cycle progression via upregulation of cyclin D1. Prevention of PDGFR-dependent PI3K activation significantly reduced neointima formation after balloon angioplasty, indicating that PI3K is involved in vascular remodeling. 9 In addition to platelet-derived growth factor (PDGF), other growth factors, such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and insulin-like growth factor-1, also contribute to restenosis formation in stented arteries because they promote SMC proliferation, migration, and differentiation. 4 Receptor tyrosine kinases (RTKs), including the βPDGFR, EGFR, FGFR, and IGFR, and receptors with associated tyrosine kinase activity signal upstream of class IA PI3K isoforms. These lipid kinases produce phosphatidylinositol-tris-phosphate. Phosphatidylinositol-tris-phosphate serves as a membrane docking site for downstream mediators, such as AKT, which propagates PI3K signaling by phosphorylation of various protein substrates.
Class IA PI3K isoforms are heterodimers consisting of a catalytic subunit (p110α, p110β, p110δ) and a smaller regulatory subunit (p85). [10] [11] [12] p110α and p110β are ubiquitously expressed, whereas p110δ expression is believed to be restricted to hematopoietic cells. 13 Analysis of mice lacking single p110 isoforms revealed nonredundant and tissuespecific functions of the various p110 isoforms, which raised hope for selective treatment options against disease promoting isoforms with tolerable impacts on physiological needs. 14 As a result, recent efforts have led to the development of isoformspecific small molecule inhibitors, particularly in the field of oncology. 15, 16 However, although recent studies were able to identify relevant PI3K isoforms in cancer, their role in vascular remodeling remains largely elusive. 17 The main goals of this study were (1) to systematically characterize the specific role of class IA PI3K isoforms for RTK-dependent signaling in SMCs and (2) to establish their significance for vascular remodeling processes in vivo, particularly neointima formation after balloon injury. To achieve these goals, we used a combination of genetic and pharmacological approaches. Although in vitro assays established p110α and, to lesser extent, p110δ to be important for growth factor-dependent SMC proliferation and migration, only p110α deficiency in mice largely suppressed balloon injury-induced neointima formation, whereas p110δ deficiency had no significant impact on restenosis.
Materials and Methods
A detailed description of the Materials and Methods is available in the online-only Data Supplement.
Results
To systematically investigate the role of class IA PI3Ks for neointima formation, we first monitored the expression profile of the 3 catalytic p110 isoforms (p110α, p110β, and p110δ) in rat aortic, as well as in human coronary SMCs. As expected, Western blot analysis revealed that p110α and p110β were abundantly expressed in SMCs ( Figure 1A ). However, although p110δ expression is believed to be restricted to leukocytes, we surprisingly found that SMCs also express p110δ. Specific siRNA-mediated knockdown of p110 subunits confirmed isoform specificity of the respective antibodies. Additionally, knockdown of specific p110 subunits did not significantly influence the expression of the remaining p110 subunits ( Figure 1A ). Furthermore, we explored binding of p110 subunits to the activated βPDGFR, representing one of the most potent RTKs in SMCs that largely contributes to neointima formation. The p110 subunits associate via their respective regulatory p85 subunit with specific tyrosine-phosphorylated binding sites within RTK polypeptides. Co-immunoprecipitation experiments using a βPDGFR-specific antibody, subsequent Western blotting for receptor-associated molecules, and densitometric analysis indicated that p110α and p110δ, as well as the regulatory p85 subunit-but not p110β-are recruited to the activated βPDGFR ( Figure 1B ). This finding was confirmed by immunocytochemical staining ( Figure 1C ). In resting cells, p110 isoforms are mainly located in the cytoplasm and the perinuclear region. Treatment with PDGF-BB stimulates a partial translocation of p110α and p110δ to the cell surface. In contrast, no p110β trafficking was observed on stimulation with PDGF-BB.
Previous studies demonstrated that at least in some cell types, p110β signals downstream of G protein-coupled receptors (GPCRs). 18 We therefore stimulated SMCs with the GPCR agonist lysophosphatidic acid and analyzed the ligand-induced phosphorylation of the PI3K downstream target AKT. Western blot and densitometric analysis presented in Figure 2A demonstrate that lysophosphatidic acid-induced activation of AKT was concentration-dependently inhibited by the p110β inhibitor TGX-221. As expected, TGX-221 did not significantly influence PDGF-induced AKT activation, and although p110δ binds to the activated βPDGFR, its catalytic activity seems to be of minor importance because p110δ inhibition via IC-87114 had no significant effect. Instead, AKT phosphorylation largely depended on p110α activity because it was completely abrogated by its specific inhibitor PIK-75 ( Figure 2B) p110 subunits expression ( Figure I in the online-only Data Supplement). Furthermore, inhibition of p110α abrogated mitogenic signaling events downstream of AKT, such as phosphorylation of glycogen synthase kinase-3β (GSK3β), induction of cyclin D1, and phosphorylation of the retinoblastoma protein ( Figure 2C ). Together, these data indicate that p110α and p110δ bind to activated RTKs, such as the βPDGFR in SMCs, and that p110α catalytic activity is mainly responsible for downstream signaling, whereas p110β seems to signal downstream of GPCRs.
p110α Mediates Smooth Muscle Cell Proliferation, Migration, and Survival
RTKs, such as the βPDGFR, are mainly involved in cellular proliferation and migration. Therefore, we analyzed the impact of the different p110 subunits on RTK-induced SMC proliferation and chemotaxis by various approaches. Figure 3A demonstrates that the p110α-selective small molecule inhibitor PIK-75 concentration-dependently prevented PDGF-induced SMC proliferation. In contrast, specific inhibition of p110β (TGX-221) and p110δ (IC-87114) was noneffective even at high concentrations (3 μmol/L). Similar results were obtained when SMC proliferation was assessed by FACS analysis, and PIK-75 also inhibited the mitogenic responses of other growth factors, such as EGF and FGF (Figures IIA and IIB in the online-only Data Supplement). Furthermore, inhibition of p110α-but not p110β or p110δ-also abolished PDGFinduced protection of SMCs against H 2 O 2 -induced apoptosis ( Figure III in the online-only Data Supplement). In a second approach, the contribution of p110 subunits to SMC proliferation was further explored by using specific siRNAs against p110α, p110β, and p110δ, respectively. As expected from the above findings, knockdown of p110α significantly diminished PDGF-induced proliferation, whereas suppression of p110β expression had no influence ( Figure 3B ). However, p110δ knockdown, which sufficiently prevented p110δ recruitment to the activated βPDGFR ( Figure IVA in the online-only Data Supplement), surprisingly also impaired SMC proliferation ( Figure 3B ). Because inhibition of p110δ kinase activity via IC-87114 had no effect even at high concentrations ( Figure  IVB α-Actin is shown as a loading control. Where indicated, p110 subunits were knocked down via specific siRNA application, respectively. Densitometric analysis were performed of 3 independent experiments and are shown below each Western blot, respectively. Data were normalized to α-actin expression and expressed as percentage of control (nonsilencing siRNA-transfected cells). #P<0.00003 verus. n.s. transfected SMCs. B, Co-immunoprecipitation of βPDGFR-associated class IA PI3K isoforms from PDGF-BB-stimulated (5 minutes) and nonstimulated SMCs. Lysate input control is shown on the left. Densitometric data (below) were normalized to βPDGFR expression and expressed as percentage of PDGF-response (**P<0.01; #P<0.001 versus PDGF-stimulated control). C, Representative immunofluorescence stainings of class IA PI3K isoforms in SMCs stimulated with PDGF (5 minutes) or vehicle. PDGF induced phosphorylation of the βPDGFR in the plasma membrane (II) and stimulated partial translocation of p110α (V) and p110δ (XI) but not p110β (VIII) isoforms to the plasma membrane. Images III, VI, IX, and XII serve as a control (second antibody only). Scale bar represents 20 μm. n.s. indicates nonsilencing control siRNA.
By the use of a second unrelated p110δ-specific siRNA, we were able to confirm this result ( Figure IVD in the online-only Data Supplement). Next, we analyzed the contribution of p110 isoforms to growth factor-induced SMC migration. In 2 distinct experimental approaches, the application of p110 inhibitors indicated that PDGF-mediated chemotaxis of SMCs depended exclusively on the activation of p110α ( Figure 3C ; Figure V in the online-only Data Supplement). In fact, PIK-75 completely abrogated SMC migration, whereas IC-87114 and TGX-221 had no influence. Consistently, knockdown of p110α by siRNA significantly diminished PDGF-induced chemotaxis, whereas suppression of p110β expression was ineffective ( Figure 3D ).
In contrast to SMC proliferation, PDGF-induced SMC migration was not affected by p110δ knockdown ( Figure 3D ).
Taken together, analysis of SMC proliferation and chemotaxis clearly demonstrated that growth factors like PDGF exert their mitogenic, migratory, and cell survival responses in SMCs via p110α-dependent pathways.
p110α Deficiency Profoundly Reduces Neointima Formation In Vivo
A concern with the use of pharmacological inhibitors is their specificity. Although p110 inhibitors are highly selective among the p110 isoforms, the overall specificity particularly of PIK-75 seems questionable because it also inhibited Erk Signaling of class IA phosphatidylinositol 3′-kinase (PI3K) isoforms in smooth muscle cells (SMCs). A, AKT phosphorylation in lysophosphatidic acid (LPA)-stimulated SMCs. p110β-specific inhibitor TGX-221 was added at the indicated concentrations. AKT blot is shown as a loading control. Densitometric analysis are shown below each Western blot, respectively. Data were normalized to AKT expression and expressed as percentage of control (5 minutes platelet-derived growth factor [PDGF]), *P<0.05; #P<0.00005 versus PDGF-stimulated control. B, AKT phosphorylation in PDGF-BB-stimulated SMCs. p110-specific inhibitors (LY294002, pan-PI3K; PIK-75, p110α; TGX-221, p110β; IC-87114, p110δ) were added as indicated. AKT is shown as a loading control. Data were normalized to AKT expression and expressed as percentage of control (5 minutes PDGF). *P<0.05; #P<0.0005 versus control. C, Impact of the p110α inhibitor PIK-75 (300 nmol/L) on PDGF-dependent phosphorylation of the retinoblastoma protein (Rb) and GSK3β, as well as induction of cyclin D1. GSK3β and α-actin are shown as loading controls. pRb and cyclin D1 were normalized to α-actin and pGSK3β to GSK3β. *P<0.05; **P<0.01 versus unstimulated control. All data are representative of 3 independent experiments. Densitometric analyses were performed of 3 independent experiments. signaling at least in SMCs ( Figure VI in the online-only Data Supplement). To reliably determine the function of p110αmediated signaling for vascular remodeling in vivo, we therefore aimed to assess the consequences of p110α deficiency on neointima formation after vascular interventions in a genetic model. Because whole body p110α knockout mice or mice expressing a kinase-inactive p110α mutant (p110α D933A/D933A ) are not viable and die between E9.5 and E12.5 because of proliferative abnormalities and defects in angiogenesis, 19 we generated smooth muscle-specific p110α-deficient mice (sm-p110α −/− ). sm-p110α mice were generated using the Cre/loxP system with Cre expressed under the control of the SM22α promoter. In adult tissue, activity of the SM22α promoter is restricted to SMCs, whereas SM22α is expressed transiently in the heart and in skeletal muscle during embryogenesis. The SM22α promoter is not active in nonmuscle cells. 20,21 sm-p110α −/− mice are viable and do not display an obvious phenotype under basal conditions. Blood pressure and heart rate are similar to wild-type (WT) controls ( Table I in the online-only Data Supplement). There was >53% and >93% reduction of p110α in SMCs isolated from sm-p110α +/− mice and sm-p110α −/− mice, respectively, whereas p110β and p110δ expression remained unchanged, as determined by Western blotting and densitometric analysis ( Figure 4A ; Figure VII in the online-only Data Supplement). Consistent with the above results using small molecule inhibitors and siRNAs, SMCs isolated from sm-p110α −/− mice did not mediate efficient phosphorylation of AKT, GSK3β, and retinoblastoma protein, as well as induction of cyclin D1 ( Figure 4B) , and displayed largely reduced proliferative and chemotactic responses to PDGF ( Figures 4C and 4D ). It is important to note that this effect was not restricted to PDGF because the proliferative responses of SMCs isolated from p110α-deficient mice to other growth factors, such as EGF and insulin-like growth factor-1, were also significantly reduced compared with cells from WT controls ( Figure 4E ).
To explore the impact of p110α deficiency in SMCs on vascular remodeling in vivo, we conducted balloon angioplasties of left common carotid arteries in sm-p110α +/+ and sm-p110α −/− mice. Balloon-triggered vessel injury promotes the migration and proliferation of SMCs in the intimal area. Histochemical analysis of cross sections from the compromised vessels revealed that p110α deficiency in SMCs resulted in robustly decreased neointima formation as compared with the situation in WT animals ( Figure 5A ). Intimal area (7997±2921 versus 37 420±7284 μm 2 , P<0.01) and intima to media ratio (0.34±0.08 versus 0.94±0.19, P<0.01) were significantly reduced ( Figures 5B and 5C ). In addition, balloon angioplasty induced remodeling in the tunica media because the medial area in WT animals was significantly increased compared with uninjured vessels. In sm-p110α −/− mice, the medial area of uninjured vessels was reduced in comparison to WT animals, and vascular injury did not induce further medial growth ( Figure 5D ). However, cellularity in the medial area of uninjured vessels did not diverge between sm-p110α +/+ (0.0029±0.0001 cells/μm 2 ) and sm-p110α −/− mice (0.0029±0.0002 cells/μm 2 ), suggesting that cell size and extracellular matrix might not be affected by p110α deficiency. PCNA stainings of neointimal sections demonstrated that p110α deficiency nearly completely suppressed SMC proliferation in vivo ( Figures 5E and 5F ). There was no difference in the area of adventitia in the injured vessels of sm-p110α +/+ and sm-p110α −/− mice ( Figure 5G ). This might reflect that in the adventitia, non-SMCs were not affected by p110α deficiency and SM22α-positive cells did not significantly contribute to adventitial growth. As expected, the endothelial cell layer in uninjured vessels and re-endothelialized areas in injured vessels were not compromised in sm-p110α −/− mice compared with WT controls ( Figure VIII in the onlineonly Data Supplement). Our in vitro data demonstrated that p110δ unexpectedly contributes to SMC proliferation, most likely via noncatalytic functions. To further investigate the impact of p110δ expression on cellular responses, we isolated aortic SMCs from p110δdeficient mice. Western blotting and subsequent densitometric analysis revealed that lack of p110δ expression did not significantly alter expression of p110α and p110β (Figures IXA and X in the online-only Data Supplement). As shown in Figure  IXB in the online-only Data Supplement, PDGF-induced proliferation was significantly impaired in SMCs isolated from p110δ-deficient mice when compared with WT controls, whereas the lack of p110δ had no effect on SMC chemotaxis ( Figure IXC in the online-only Data Supplement). These data are consistent with siRNA-based approaches, indicating again a noncatalytic function of p110δ for RTK-induced SMC proliferation. To explore a potential impact of p110δ expression on SMC-mediated vascular remodeling in vivo, we conducted balloon angioplasties of left common carotid arteries in p110δ +/+ and p110δ −/− mice. However, histochemical analysis of cross sections from the compromised vessels revealed that p110δ deficiency did not affect intimal area and intima/media ratio and medial and adventitial area compared with WT controls (Figures IXD-IXH in the online-only Data Supplement).
In summary, these data indicate that p110α plays a key role for neointima formation after vascular injury. Despite its effect on SMC proliferation in vitro, p110δ expression and activity are of minor importance for vascular remodeling in vivo.
Role of p110 Isoforms in Human Coronary Cells
To evaluate the significance of the above findings for human coronary disease, we also assessed the effects of p110α inhibition by PIK-75 in human coronary SMCs as well as human coronary endothelial cells (hcECs). PDGF-induced proliferation and migration of human coronary SMCs depended on p110α catalytic activity ( Figures 6A and 6B ). Analysis of apoptosis revealed that under these assay conditions, PIK-75 ≤1 μM did not induce apoptosis (data not shown). Furthermore, the inhibitory effect of PIK-75 was not restricted to PDGF because the mitogenic and chemotactic effects of multiple growth factors, including PDGF, FGF, EGF, insulin, and serum, were also inhibited ( Figures 6C and 6D ). Because our results in SMCs indicated that p110α acts as a crucial downstream mediator of multiple RTKs and EC function is crucial for proper endothelial repair after vascular injury, we also assessed the impact of p110α inhibition on vascular endothelial growth factor (VEGF)-dependent proliferation and migration of hcECs. These experiments indicated that p110α inhibition via PIK-75 also inhibited VEGF-induced proliferation and chemotaxis of these cells in a concentrationdependent manner ( Figures 6E and 6F) , indicating that the therapeutic application of p110α inhibitors in the context of vascular interventions may also affect re-endothelialization.
Discussion
Herein, we sought to reveal the importance of class IA PI3K isoforms in SMCs for pathological vascular remodeling. Our data provide strong evidence from genetic models that among RTK inducible class IA PI3K isoforms, only p110α is important for neointima formation and media growth after balloon angioplasty via mediating SMC proliferation and migration. Although p110δ is expressed in SMCs and is recruited to the activated βPDGFR, its catalytic activity is dispensable for SMC proliferation, migration, and neointima formation in vivo. Nevertheless, p110δ seems to exert some noncatalytic functions in RTK signaling. In contrast to p110α and p110δ, p110β does not couple to RTKs in SMCs, but rather signals downstream of GPCRs. Although p110α was identified as a crucial target for the prevention of neointima formation, its biological importance may not be restricted to SMCs.
Expression of p110α and p110β in SMCs as assessed herein was as expected because previous studies indicated that these isoforms are ubiquitously expressed. In contrast, p110δ expression was believed to be restricted to leukocytes, although its expression in SMCs has not been analyzed in detail before. Apart from leukocytes, p110δ expression could not be detected in numerous tissues and cell types, including liver, lung, muscle, and brain, as well as fibroblasts and ECs. 22 Therefore, p110δ expression in SMCs appeared unlikely. However, our data provide evidence that this isoform is abundantly expressed in SMCs from human, mouse, and rat origin. Moreover, coimmunoprecipitation experiments demonstrated that p110δ couples to the activated βPDGFR, suggesting a possible function in RTK-induced PI3K signaling. In contrast, p110β-although expressed in SMCs-did not bind to the activated βPDGFR, and its inhibition did not influence PDGF-dependent AKT activation. Consistent with recent studies demonstrating that p110β couples to GPCRs at least in some cell types, 18, 23 we found that p110β inhibition via TGX-221 abrogated lysophosphatidic acid-induced AKT activation, demonstrating that p110β participates in GPCR signaling in SMCs. Hence, within class IA PI3K isoforms, p110α and p110δ couple to RTKs in SMCs, whereas p110β seems to signal downstream of GPCR. Our experiments using isoform-specific p110 inhibitors and gene knockdown by siRNA revealed that p110α is the critical isoform mediating RTK-dependent cell responses in rat, mouse, and human SMCs. This is in accordance with several studies demonstrating a central function for p110α in mitogenic and migratory responses in various cell types, including ECs, retinal cells, intestinal epithelial cells, ovarian cancer cells, and human aortic SMCs. [24] [25] [26] [27] [28] Additionally, the gene encoding p110α (PIK3CA) is one of the most commonly mutated genes identified in numerous human tumors, indicating an important role of p110α in proliferative diseases like cancer, [29] [30] [31] which has led to great efforts to develop isoform-specific PI3K inhibitors. 32 Data presented herein provide further evidence that p110α signaling in SMCs is of major importance during pathological vascular remodeling. Application of PIK-75 resulted in a concentration-dependent inhibition of SMC proliferation with half-maximal effects at 30 to 100 nmol/L in human coronary cells and 100 to 300 nmol/L in rat SMCs. Importantly, these concentrations are relevant in vivo because serum levels ≤117 nmol/L were achieved after systemic application of PIK-75 in mice and appeared sufficient to attenuate pathological remodeling after vessel ligation. 28 Furthermore, our data are consistent with previous publications on tumor cell proliferation presenting IC 50 values between 19 and 100 nmol/L, 33, 34 whereas lower concentrations were sufficient in cell-free systems. 33 It is well established that PI3K-dependent proliferative responses are mediated through the activation of AKT 35 and that PI3K also contributes to cell migration via activating small GTPases of the Rho family, like Rac, Rho, or Cdc42, 27, 36, 37 which control migratory responses mainly via organization of the actin cytoskeleton. 38 Herein, monitoring of PDGFinduced downstream signaling events in SMCs revealed that the phosphorylation of GSK3β, induction of cyclin D1, and phosphorylation of the retinoblastoma protein depend on p110α kinase activity. These data are in line with previous findings from our laboratory, demonstrating that the βPDGFR induces cell cycle progression of SMCs via PI3K-dependent upregulation of cyclin D1 9 . This is consistent with the concept that AKT-dependent phosphorylation/inactivation of GSK3β leads to upregulation of the cell cycle promoter cyclin D1 by preventing its cytoplasmic relocalization and degradation. 39, 40 Furthermore, SMC proliferation stimulated by diverse growth factors like EGF, FGF, or insulin-like growth factor-1 was almost abrogated in these cells, indicating a common function of p110α in growth factor-induced cell cycle progression. Consequently, intimal area was robustly reduced in sm-p110α −/− mice compared with WT controls 28 days after injury. Simultaneously, intimal cellular proliferation was almost abrogated in these mice as measured by PCNA staining. Because there is no evidence that cell cycle progression of SMCs is differentially regulated at different time points after injury and considering an almost 80% reduced intimal area in injured sm-p110α −/− mice, one must assume that lack of p110α expression should also impair SMC proliferation at early time points. Taken together, these data indicate that p110α is crucial for growth factor-induced cell cycle progression in vitro and in vivo.
When identifying signaling pathways and molecular targets, a concern with the use of pharmacological inhibitors is their specificity. In particular, although PIK-75 is highly selective among the p110 isoforms, its overall specificity seems questionable (see Figure VI in the online-only Data Supplement). Therefore, it is important to note that we obtained similar results by using 3 different approaches, namely inhibition of p110α kinase activity by PIK-75, gene knockdown by siRNA, and targeted deletion of p110α in SMCs. To evaluate the importance of p110α for neointima formation in vivo, we generated SMC-specific p110α knockout mice. sm-p110α −/− mice were viable, underwent normal development, and had no obvious phenotype under basal conditions, but showed reduced medial area in carotid arteries compared with their WT littermates. This suggests that p110α as a common downstream mediator of multiple RTKs might affect normal vessel development most likely via mediating SMC proliferation. After balloon injury, lack of p110α in SMCs largely reduced neointima formation. Our data that were obtained by a genetic model using sm-p110α −/− mice are consistent with a recent study demonstrating that pharmacological inhibition of p110α by systemic administration of PIK-75 selectively interfered with arterial thrombosis and neointima formation in a ligation model of vascular injury. 28 However, although these investigators reported that p110α inhibition does not affect EC function and re-endothelialization after vascular injury, we found that VEGF-dependent proliferation and migration of hcECs are also markedly impaired by PIK-75. The latter finding is in accordance with recent genetic studies demonstrating that p110α is essential for EC migration, proliferation, and survival and that EC-specific p110α deficiency led to embryonic lethality because of severe defects in vascular development. 19, 27 This discrepancy may be explained by differences in cells (HAEC versus hcEC), by different concentrations of PIK-75, and by the fact that in the study by Holy et al, 28 FCS-which also activates GPCRs-was used as an inducer of EC responses, which may potentially override RTK-mediated effects. Our results show that hcEC proliferation and migration on stimulation with VEGF, representing the most relevant growth factor for ECs that regulates vascular development and endothelial repair mechanisms, were concentration-dependently inhibited by PIK-75. Although we were not able to analyze the effects of p110α on re-endothelialization in vivo because EC-specific p110α-deficient mice are not viable, 27 this finding may have important implications because inhibition of VEGFdependent EC responses is believed to ameliorate proper endothelial coverage after vascular injury. On the other hand, SMC specific ablation of p110α led to an almost complete reduction of neointima formation after vessel injury without affecting re-endothelialization.
Thus, our results indicate that cell type-specific interference with p110α signaling in SMCs may be required to use this pathway as an attractive approach to robustly reduce neointima formation without affecting proper re-endothelialization.
Although p110δ also binds to the activated βPDGFR, its function remains obscured. On the one hand, lack of p110δ expression significantly diminished PDGF-dependent proliferation, as shown by siRNA-mediated knockdown of p110δ in rat SMCs, and in cells isolated from p110δ-deficient mice. On the other hand, p110δ catalytic activity seems dispensable for SMC proliferation and migration. These data suggest a kinase-independent function of p110δ, as previously demonstrated for p110β. Expression of kinase-inactive p110β rescued the impaired proliferation of mouse embryonic fibroblasts lacking p110β and also restored internalization of transferrin and activated EGFR, suggesting a kinase-independent function of p110β in endocytosis, which is required for cell proliferation. 23, 41 Although these data indicate that a potential scaffolding function on cell proliferation is not restricted to p110δ, the underlying noncatalytic mechanisms of class IA p110 subunits remain elusive. Whether kinase-independent actions of p110δ are relevant in physiological or pathological processes is not yet clear. At least during neointima formation after balloon angioplasty, p110δ deficiency seems to be of minor importance, although it diminished SMC proliferation in vitro. This may be explained by the fact that numerous cellular responses, including mitogenic, migratory, and survival signals, are required for neointima formation. 35 In summary, the data presented herein provide a systematic characterization of the role of class IA PI3K isoforms for cell proliferation, migration, and survival of SMCs, representing highly relevant processes during vascular remodeling. By using a genetic model, p110α was identified as the critical isoform mediating these cellular events, and its lack in SMCs completely abrogated neointima formation after balloon injury in sm-p110α −/− mice. However, cell type-specific targeting of p110α may be required because VEGF-dependent responses of hcECs are also mediated via this isoform.
